Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.

EQT lägger bud på Karo Pharma

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Moberg Pharma fyller på kassan genom nyemission

Moberg Pharma tar in 121 miljoner kronor i en nyemission för att finansiera fortsatt registrering och lansering av företagets läkemedel mot nagelsvamp.